Evidence map›Paper›PMID 29460133›Full record

ArticleInternational urology and nephrology2018

Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.

Congyun Xu, Yan Xu, Zhou Shen, Hangcheng Zhou, Jun Xiao, Tao Huang

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Animal models of benign prostatic hyperplasia.Prostate cancer and prostatic diseases · 2021
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Congyun XuDepartment of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China.
Yan XuDepartment of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China.
Zhou ShenDepartment of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China.
Hangcheng ZhouDepartment of Pathology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China.
Jun XiaoDepartment of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China.
Tao HuangDepartment of Urology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, #17 Lujiang Road, Hefei, 230001, China. dramantony@126.com.
Anhui Provincial Hospital · CNUniversity of Science and Technology of China · CN

Funding

Natural Science Foundation of Anhui Province 1408085QH152
6 · The paper itself

Abstract

objectivesTo investigate the efficacy of insulin sensitizer on prostatic tissue in animal model with benign prostatic hyperplasia (BPH) secondary to metabolic syndrome (MetS).

methodsModels were established by providing Sprague-Dawley rats with high fat diet (HFD) combined with metformin or not. All objects were killed 40 days later with prostatic tissue being removed, weighed before stained, as well as the expression level of insulin-like growth factor I (IGF-1) and receptor (IGF-1R) being measured, and the level of insulin resistance (IR) has also been evaluated.

resultsModel has been successfully established. Level of prostatic hyperplasia and IR as well as IGF-1 and IGF-1R expressions in the blank and saline control subunits of HFD group was higher than that of normal diet group (P < 0.05). In the subunit of metformin, along with the suppression of IR, the level of prostatic hyperplasia and the expression of IGF-1 pathway have both decreased (P < 0.05).

conclusionMetS can promote the growth of prostate during the formation of central obesity and IR. IGF-1 pathway may have an important role in the induction of BPH following IR. The application of metformin can suppress the expression of IGF-1 and IGF-1R, thus preventing the promotive effect of IR on prostate tissue in animal model of MetS.

Indexed as

Insulin ResistanceAnimalsDiet, High-FatDisease Models, AnimalHypoglycemic AgentsInsulin-Like Growth Factor IMaleMetabolic SyndromeMetforminProstateProstatic HyperplasiaRatsRats, Sprague-DawleyReceptor, IGF Type 1Hypoglycemic Agentsinsulin-like growth factor-1, ratInsulin-Like Growth Factor IMetforminReceptor, IGF Type 1Benign prostatic hyperplasiaInsulin-like growth factor IInsulin resistanceMetabolic syndromeMetforminReceptor, IGF type 1

Identifiers

PMID29460133
OpenAlexW2794052856

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.